Markets
Alnylam Stock Plunges 16%, Wiping Out $5.1 Billion, As Management Says Amvuttra Demand Lags
The RNA drugmaker will hold 2027 guidance until mid-February, and management says it is "not yet satisfied" with Amvuttra growth.
ALNY
Alnylam Pharmaceuticals (ALNY) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Alnylam Will Skip 2027 Guidance At JPMorgan, Waiting On A Medicare 340B Rule
The drugmaker will give 2027 product revenue guidance in mid-February, after a pending 340B rule and a UnitedHealth policy change.
Earnings
Alnylam CEO Says Company Is 'Not Yet Satisfied' With Amvutra Demand, Sees No Fourth-Quarter Acceleration
Alnylam expects TTR sales at the low end of its $4.2 billion to $4.5 billion range as its larger field team has not yet lifted patient starts.
SEC Filings
Alnylam's $2.17 Billion Quarterly Profit Rests On A $1.87 Billion Tax Benefit
Pretax income was $295.8 million, and income from operations slipped to $345.8 million from $368.0 million a year earlier.
SEC Filings
Alnylam's TTR Drug Sales Jump 59% To $1,150 Million, But A Tax Gain Props Up $2.2 Billion Profit
Operating income slipped 6% on a standard accounting basis as costs rose, and the company reiterated its 2026 guidance.